RxDoctor Payments Data

Richard Lee, MD

Thoracic Surgery (Cardiothoracic Vascular Surgery) · Seattle, WANPI 1437476934

Payments from drug & device makers

What this record shows

17 manufacturers reported payments, led by Edwards Lifesciences at 32.9% of the total. Reporting peaked in 2019 at $3,423 and has fallen 61.0% since, to $1,333 in 2025.

$7,626in general payments, 2019–2025

Across 68 payments — averaging $112.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$3K
  • W. L. Gore & Associates, Inc.$1K
  • Atricure, Inc.$1K
  • Medtronic$1K
  • Inari Medical, Inc.$320
  • Zimmer Biomet$196
  • plus $816 from 11 others

What the payments were for

  • Travel & lodging$3,97152%
  • Food & beverage$3,65548%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,626 in reported general payments places this provider in the 60th percentile of 105 thoracic surgery (cardiothoracic vascular surgery) providers in Washington.

See all thoracic surgery (cardiothoracic vascular surgery) providers in Washington

Medicare billing

Part B allowed, 2024
$161,509
Medicare patients
162
Services billed
314

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Chlorhexidine Gluconate13$45

Paid to pharmacies, not to this prescriber.

Other thoracic surgery (cardiothoracic vascular surgery) in Seattle

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →